CHRNA10: A Potential Drug Target for Central Nervous System Functions

Target Name: CHRNA10

NCBI ID: G57053

CHRNA10

Other Name(s): cholinergic receptor nicotinic alpha 10 subunit | Cholinergic receptor nicotinic alpha 10 subunit, transcript variant 1 | CHRNA10 variant 1 | Neuronal acetylcholine receptor protein, alpha-10 chain | Nicotinic acetylcholine receptor subunit alpha-10 | cholinergic receptor, nicotinic alpha 10 | NACHR alpha-10 | Neuronal acetylcholine receptor subunit alpha-10 | acetylcholine receptor, nicotinic, alpha 10 (neuronal) | ACH10_HUMAN | Neuronal acetylcholine receptor subunit alpha-10 (isoform a) | cholinergic receptor, nicotinic, alpha 10 (neuronal) | nAChR alpha-10 | nicotinic acetylcholine receptor subunit alpha-10 | cholinergic receptor, nicotinic, alpha polypeptide 10 | HNARA10

CHRNA10: A Potential Drug Target for Central Nervous System Functions

CHRNA10 (cholinergic receptor nicotinic alpha 10 subunit) is a protein that is expressed in the central nervous system (CNS) and is involved in the function of nicotinic receptors, which are a family of neurotransmitter receptors that play a crucial role in modulating a wide range of physiological processes in the brain and body. In this article, we will discuss the biology and potential drug targets of CHRNA10.

The CHRNA10 Receptor

CHRNA10 is a member of the nicotinic receptor subfamily, which includes over 70 different subunits that span four different classes: alpha, beta, gamma, and delta. The alpha subunits are responsible for the ligand binding and dissociation processes, while the beta, gamma , and delta subunits are involved in the internal signaling mechanisms.

CHRNA10 is a 120-kDa protein that is expressed in the CNS and is primarily located in the prefrontal cortical region of the brain. It is involved in the function of many different neurotransmitter systems, including GABA, dopamine, and opioids. CHRNA10 is also known to play a role in the modulation of pain modulation, anxiety, and depression.

The Potential Drug Targets

CHRNA10 is a drug target of great interest due to its involvement in a wide range of physiological processes. One of the main targets for CHRNA10 is the modulation of pain modulation. CHRNA10 has been shown to play a role in the modulation of pain sensitivity in both experimental models and animal models.

In addition to its role in pain modulation, CHRNA10 is also a potential target for the modulation of anxiety and depression. Studies have shown that CHRNA10 is involved in the modulation of anxiety-like behavior in animal models of depression. Furthermore, CHRNA10 has been shown to play a role in the modulation of depressive-like behavior in human subjects.

Another potential drug target for CHRNA10 is the modulation of neurotransmitter release. Studies have shown that CHRNA10 is involved in the modulation of neurotransmitter release in the CNS, including the release of GABA and dopamine. This suggests that CHRNA10 may be a useful target for the treatment of disorders that are characterized by neurotransmitter imbalances, such as anxiety and depression.

Conclusion

In conclusion, CHRNA10 is a protein that is expressed in the CNS and is involved in the function of nicotinic receptors. It is a potential drug target due to its involvement in the modulation of pain modulation, anxiety, and depression. Further research is needed to fully understand the role of CHRNA10 in the modulation of physiological processes in the CNS and to develop effective treatments for disorders that are characterized by neurotransmitter imbalances.

Protein Name: Cholinergic Receptor Nicotinic Alpha 10 Subunit

Functions: Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane. In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma

The "CHRNA10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHRNA10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets